** Sorry if this is a double/triple post; the first two disappeared. Third attempt. **
Anyone ever heard anything (positive or negative) about LXH254? As I mentioned in my last post, I’ve had progression after Yervoy, and the next step will be BRAF/MEK inhibitors. While talking with my PA, I mentioned that I’d be keeping an eye out for clinical trials, while we move ahead with the targeted therapy, and I of course asked her to keep me in mind if she saw anything for which she thought I’d be a good candidate. Unfortunately, I’m at the UofMinn, and they don’t seem to have many melanoma trials going on right now (apparently a lot cancelled due to COVID), so I told her that I’d bookmarked several other spots also. Mayo-Rochester (I’m in the southern Twin Cities, and that would be doable logistically I think), UCLA (brother, who would let me stay for as long as necessary, lives in LA and I did grad school at UCLA, so connection to the area), UCSF (best friend from college is there and he has said I can stay as long as I want; I also worked at UCSF so more connections). Also have a connection to Houston, but not a crash pad, so I’ve got UMN, Mayo, UCLA, and UCSF bookmarked.
Anyway, the PA wrote back saying that there was a stage 2 study at Mayo involving LXH254 that I might look at:
“LXH254, a Potent and Selective ARAF-Sparing Inhibitor of BRAF and CRAF for the Treatment of MAPK-Driven Tumors”
https://pubmed.ncbi.nlm.nih.gov/33355204/
Just wondering if anyone had heard anything about this. Looks like another BRAF inhibitor, but they seem to emphasize this ARAF-sparing aspect. Not really sure why that is desirable, if it gives it wider effectiveness (which I thought was already pretty high for these targeted therapies), or longer lasting, or something else? Anyway, I know there are people here who are more likely than me to know, so I thought I’d ask. Not a lot in a google search. Thanks.
.
